Gilead Sciences, Inc. (FRA:GIS)
104.88
+0.20 (0.19%)
At close: Oct 23, 2025
Gilead Sciences Revenue
Gilead Sciences had revenue of $7.08B USD in the quarter ending June 30, 2025, with 1.84% growth. This brings the company's revenue in the last twelve months to $28.86B, up 3.81% year-over-year. In the year 2024, Gilead Sciences had annual revenue of $28.75B with 6.04% growth.
Revenue (ttm)
$28.86B
Revenue Growth
+3.81%
P/S Ratio
5.25
Revenue / Employee
$1.64M
Employees
17,600
Market Cap
129.07B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 28.75B | 1.64B | 6.04% |
| Dec 31, 2023 | 27.12B | -165.00M | -0.60% |
| Dec 31, 2022 | 27.28B | -24.00M | -0.09% |
| Dec 31, 2021 | 27.31B | 2.62B | 10.60% |
| Dec 31, 2020 | 24.69B | 2.24B | 9.98% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Mercedes-Benz Group AG | 139.36B |
| Deutsche Telekom AG | 120.55B |
| Allianz SE | 109.02B |
| Siemens Aktiengesellschaft | 78.30B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.33B |
| Siemens Energy AG | 38.39B |
| SAP SE | 35.89B |
| Deutsche Bank Aktiengesellschaft | 30.07B |
Gilead Sciences News
- 13 hours ago - TD Cowen Raises Price Target for Gilead Sciences (GILD) to $125 | GILD Stock News - GuruFocus
- 19 hours ago - Gilead to Showcase Interim Long-Term Efficacy Data for Livdelzi® (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta - Business Wire
- 1 day ago - CVS (CVS) Delays Adding Gilead's Yeztugo Over Pricing Concerns - GuruFocus
- 1 day ago - CVS reportedly cites pricing concerns in excluding coverage for Gilead’s new HIV drug - Seeking Alpha
- 1 day ago - Gilead Sciences (GILD) Halts Phase 1 HIV Treatment Trial - GuruFocus
- 1 day ago - Gilead Sciences (GILD) Halts Phase 1 Study for HIV Treatment - GuruFocus
- 1 day ago - Gilead discontinues early-stage trial for long-acting injectable for HIV - Seeking Alpha
- 2 days ago - Final Trade: F, HAL, MA, GILD - CNBC